tremelimumab astrazeneca
astrazeneca ab - tremelimumab - carcinoma, non-small-cell lung - antineoplastic agents - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
astrazeneca water for injections 10ml ampoule
astrazeneca pty ltd - water for injections -
astrazeneca water for injections 5ml ampoule
astrazeneca pty ltd - water for injections -
astrazeneca sodium chloride 0.9% 10ml injection bpampoule
astrazeneca pty ltd - sodium chloride -
astrazeneca sodium chloride 0.9% 5ml injection bp ampoule
astrazeneca pty ltd - sodium chloride -
pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)
astrazeneca ab - reassortant influenza virus (live attenuated) of the following strain: a/vietnam/1203/2004 (h5n1) strain - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation in children and adolescents from 12 months to less than 18 years of age.pandemic influenza vaccine h5n1 astrazeneca should be used in accordance with official guidance
bricanyl turbuhaler
astrazeneca limited - terbutaline sulfate 0.25mg; terbutaline sulfate 200ug equivalent to 0.25 mg metered dose - powder for inhalation - 0.25 mg/dose - active: terbutaline sulfate 0.25mg terbutaline sulfate 200ug equivalent to 0.25 mg metered dose excipient: lactose monohydrate - relief of bronchospasm occurring in bronchial asthma, bronchitis and other bronchopulmonary conditions where bronchospasm is a complicating factor. acute prophylaxis in situations known to induce bronchospasm, e.g. exercise induced asthma.
astrazeneca goserelin goserelin 3.6mg (as acetate) implant syringe
astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer, where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. breast cancer: treatment of advanced breast cancer (t3b, t4 or any t with n2, 3 or m plus) in premenopausal women suitable for hormonal manipulation. adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. endometriosis: in the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. uterine fibroids: in the management of fibroids, astrazeneca goserelin shrinks the lesions and reduces the symptoms, including pain. astrazeneca goserelin also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. it is used as an adjunct to surgery to facilitate the operative technique and reduce operativeblood loss. endometrial thinning: use as an endometrial thinning agent prior to endometrial ablation. assisted reproduction: pituitary down regulation in preparation for controlled ovarian superstimulation.
bricanyl 0.5mg/1ml injection ampoule
astrazeneca pty ltd - terbutaline sulfate, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - indications ast at 24 june 2004: for relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm. bricanyl injection: bricanyl injection solution is recommended for acute use only.
pancuronium bromide (astrazeneca)
astrazeneca limited - pancuronium bromide 2 mg/ml - solution for injection - 4 mg/2ml - active: pancuronium bromide 2 mg/ml excipient: acetic acid sodium acetate trihydrate sodium chloride sodium hydroxide water for injection - an adjunct to surgical anaesthesia to induce skeletal muscle relaxation to facilitate operative manipulations. the necessary conditions for intubation can be achieved with pancuronium alone or following suxamethonium. to promote mechanical ventilation by reducing or eliminating spontaneous breathing effort in intensive care patients.